BRAF and melanoma: The treatment combination of trametinib, a pyrido-pyrimidine derivative, and dabrafenib, a BRAF inhibitor, is currently under evaluation in phase 2 clinical trials for treating patients with BRAF mutant resectable stage III melanoma (ClinicalTrials.gov identifier: NCT02858921).